The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin
Open accessAbstract
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG-expansion in the huntingtin gene (HTT) that results in a toxic gain of function in the mutant huntingtin protein (mHTT). Reducing the expression of mHTT is therefore an attractive therapy for HD. However, wild-type HTT protein is essential for development and has critical roles in maintaining neuronal health. Therapies for HD that reduce wild-type HTT may therefore generate unintended negative consequences. We have identified single-nucleotide polymorphism (SNP) targets in the human HD population for the disease-specific targeting of the HTT gene. Using primary cells from patients with HD and the transgenic YAC18 and BACHD mouse lines, we developed antisense oligonucleotide (ASO) molecules that potently and selectively silence mHTT at both exonic and intronic SNP sites. Modification of these ASOs with S-constrained-ethyl (cET) motifs significantly improves potency while maintaining allele selectively in vitro. The developed ASO is potent and selective for mHTT in vivo after delivery to the mouse brain. We demonstrate that potent and selective allele-specific knockdown of the mHTT protein can be achieved at therapeutically relevant SNP sites using ASOs in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Self-citationLoss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Self-citationReversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G., & Hayden, M. R. (1995) · Cell · doi:10.1016/0092-8674(95)90542-1 · Cited by 872
Self-citationMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X.-H., Tao, J., Yamazaki, I., Li, S.-H., Sun, Y. E., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0857-08.2008 · Cited by 613
McBride, J. L., Boudreau, R. L., Harper, S. Q., Staber, P. D., Monteys, A. M., Martins, I., Gilmore, B. L., Burstein, H., Peluso, R. W., Polisky, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801775105 · Cited by 607
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models
Sarkar, S., Perlstein, E. O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R. L., Webster, J. A., Lewis, T. A., O'Kane, C. J., Schreiber, S. L., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio883 · Cited by 596
Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00615-3 · Cited by 595
Self-citationDragatsis, I., Levine, M. S., & Zeitlin, S. (2000) · Nature Genetics · doi:10.1038/81593 · Cited by 576
White, J. K., Auerbach, W., Duyao, M. P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., & MacDonald, M. E. (1997) · Nature Genetics · doi:10.1038/ng1297-404 · Cited by 534
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708285104 · Cited by 415
Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Savani, A. A., & Login, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000259143.52138.5c · Cited by 299
Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
Antisense Drug Technology: Principles: Strategies, and Applications
(2021) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 268
Tsvetkov, A. S., Miller, J., Arrasate, M., Wong, J. S., Pleiss, M. A., & Finkbeiner, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004498107 · Cited by 266
Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D., & Swayze, E. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801294h · Cited by 266
Pfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P. D., & Aronin, N. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.030 · Cited by 261
Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides.
Monia, B. P., Johnston, J. F., Ecker, D. J., Zounes, M. A., Lima, W. F., & Freier, S. M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)88650-7 · Cited by 254
Self-citationHu, J., Matsui, M., Gagnon, K. T., Schwartz, J. C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I., & Corey, D. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1539 · Cited by 243
Warby, S. C., Montpetit, A., Hayden, A. R., Carroll, J. B., Butland, S. L., Visscher, H., Collins, J. A., Semaka, A., Hudson, T. J., & Hayden, M. R. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.02.003 · Cited by 240
Self-citationWild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In Vivo
Leavitt, B. R., Guttman, J. A., Hodgson, J. G., Kimel, G. H., Singaraja, R., Vogl, A. W., & Hayden, M. R. (2001) · The American Journal of Human Genetics · doi:10.1086/318207 · Cited by 237
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications
Szymkowski, D. E. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02123-7 · Cited by 218
Sustained effects of nonallele‐specific Huntingtin silencing
Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi‐Carter, R., Hantraye, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21569 · Cited by 216
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
Wang, Y.-L., Liu, W., Wada, E., Murata, M., Wada, K., & Kanazawa, I. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.06.021 · Cited by 191
Wild‐type huntingtin protects neurons from excitotoxicity
Leavitt, B. R., van Raamsdonk, J. M., Shehadeh, J., Fernandes, H., Murphy, Z., Graham, R. K., Wellington, C. L., Raymond, L. A., & Hayden, M. R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03605.x · Cited by 186
Self-citationHuntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing
Rigamonti, D., Sipione, S., Goffredo, D., Zuccato, C., Fossale, E., & Cattaneo, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100044200 · Cited by 174
Gagnon, K. T., Pendergraff, H. M., Deleavey, G. F., Swayze, E. E., Potier, P., Randolph, J., Roesch, E. B., CHATTOPADHYAYA, J. B., Damha, M. J., Bennett, C. F., et al. (2010) · Biochemistry · doi:10.1021/bi101208k · Cited by 140
Self-citationHuntingtin inhibits caspase‐3 activation
Zhang, Y., Leavitt, B., Raamsdonk, J. V. V., Dragatsis, I., Goldowitz, D., MacDonald, M., Hayden, M. R., & Friedlander, R. M. (2006) · EMBO Journal · doi:10.1038/sj.emboj.7601445 · Cited by 128
Self-citationLombardi, M. S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Maria, E. D., Donato, S. D., & Kaemmerer, W. F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.004 · Cited by 125
van Bilsen, P. H. J., Jaspers, L., Lombardi, M. S., Odekerken, J. C. E., Burright, E. N., & Kaemmerer, W. F. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.116 · Cited by 116
Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism
Hu, J., Liu, J., & Corey, D. R. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.10.013 · Cited by 107
Zhang, S., Feany, M. Β., Saraswati, S., Littleton, J. T., & Perrimon, N. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.000653 · Cited by 101
Hodgson, J., Smith, D. J., McCutcheon, K., Koide, H. B., Nishiyama, K., Dinulos, M. B., Stevens, M. E., Bissada, N., Nasir, J., Kanazawa, I., et al. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.12.1875 · Cited by 99
Self-citationAllele-specific RNA interference for neurological disease
Rodríguez-Lebrón, E., & Paulson, H. L. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302702 · Cited by 94
Lima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Siwkowski, A. M., & Crooke, S. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025015 · Cited by 89
Graham, R. K., Slow, E., Deng, Y., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Leavitt, B. R., Raymond, L. A., & Hayden, M. R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.007 · Cited by 85
Self-citationNeurons Lacking Huntingtin Differentially Colonize Brain and Survive in Chimeric Mice
Reiner, A. J., Mar, N. D., Meade, C. A., Yang, H., Dragatsis, I., Zeitlin, S., & Goldowitz, D. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07608.2001 · Cited by 82
Fluoxetine in the treatment of Huntington’s disease
De Marchi, N., Daniele, F., & Ragone, M. A. (2001) · Psychopharmacology · doi:10.1007/s002130000575 · Cited by 57
Linking SNPs to CAG repeat length in Huntington's disease patients
Liu, W., Kennington, L. A., Rosas, H. D., Hersch, S. M., Cha, J.-H. J., Zamore, P. D., & D, N. A. M. (2008) · Nature Methods · doi:10.1038/nmeth.1261 · Cited by 39
Tailor-made RNAi knockdown against triplet repeat disease-causing alleles
Takahashi, M., Watanabe, S., Murata, M., Furuya, H., Kanazawa, I., Wada, K., & Hohjoh, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012153107 · Cited by 26
Huntington's disease: Silencing a brutal killer
Pfister, E. L., & Zamore, P. D. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.017 · Cited by 24
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationHuntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationTargeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Metadata
- Authors
- Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 19
- Issue
- 12
- Pages
- 2178-2185
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1970986383
- Cited by
- 293
- References
- 50
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.